Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research

Special Issue: Anticancer Agents

• Minireview • Previous Articles    

Recent Advances on Small-Molecule Tubulin Inhibitors

Xiu-Li Sun,a,b Yin-Rong Xie,a,b Ning Zhang,a,b Cheng-Ting Zi,*,a,c Xuan-Jun Wang,*,a,c and Jun Sheng*,a   

  1. a Key Laboratory of Pu-erh Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, Yunnan 650201, China;
    b College of Food Science and Technology, Yunnan Agricultural University, Kunming, Yunnan 650201, China;
    c College of Science, Yunnan Agricultural University, Kunming, Yunnan 650201, China
  • Received:2020-12-29 Revised:2021-02-21 Online:2021-01-20
  • Contact: *,Email: zichengting@126.com (C. Z.), xuanjunwang@qq.com (X. W.) and shengj@ynau.edu.cn (J. S.)
  • Supported by:

Abstract: Microtubules are heterodimers composed of α/β tubulin and make up the cytoskeleton. It plays an important role in maintaining cellular morphology, cell division, signal transduction and other processes. At present, six tubulin inhibitor binding sites have been identified. The inhibitors can be divided into two categories: a type of microtubule polymerization agent includes colchicine site, vinblastine site, maytansine site and prionetin site inhibitors; another category is paclitaxel and laulimalide/peloruside binding site inhibitors are called microtubule depolymerization. Herein, we summarize relevant inhibitors acting on these 6 sites and their research status. With extensive research on tubulin binding sites and inhibitors, anti-tumor tubulin inhibitors will possess very broad clinical prospects.


Key words: microtubule, tubulin, binding site, inhibitors

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States